Opening blocked neck arteries with a metal stent or surgery were equally durable, in research presented at the American Stroke Association's International Stroke Conference 2012.
Two years after the procedures, less than 7 percent of patients had developed repeat blockages (restenosis), researchers said.
"Unlike bare metal stents placed in coronary arteries, where re-blockage occurs about 20 percent of the time, we found the re-blockage rates in the carotid artery were quite small," said Brajesh K. Lal, M.D., lead author of this analysis and associate professor of vascular surgery at the University of Maryland School of Medicine in Baltimore. "Patients and physicians can be reassured that both procedures are durable and that re-blockage rates are equivalent, so they can use different criteria to determine which procedure is right for a patient."
The study is the largest to look at restenosis rates after either procedure.
The study participants — part of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) — had partial blockages in a neck artery. Symptomatic patients had experienced a non-disabling stroke or transient ischemic attack (mini-stroke) because of the blockage, while asymptomatic patients had not.
Previously, this head-to-head comparison of the two procedures showed no difference in the combined rates of stroke, heart attack or death between patients undergoing surgical removal of a blockage (carotid endarterectomy) or stenting.
About 10 percent of strokes are caused by blockages in the neck arteries, which supply blood to the brain. Revascularization procedures preserve blood flow and lower the risk of stroke.
In the current study, 1,086 patients received stenting and 1,105 endarterectomy. All were assessed at one, six, 12 and 24 months after the procedure with an ultrasound to identify those who had developed a 70 percent or greater blockage in the treated section.
After two years, the researchers found:
"These may be groups we need to focus more on by monitoring them closely and aggressively controlling risk factors after the procedures," said Lal, who is also chief of vascular surgery at the Baltimore VA Medical Center in Maryland.
Physicians from different specialties perform revascularization procedures. In the study, results didn't differ by specialty.
"CREST was unique in having a built-in training and credentialing process that mandated participating physicians perform 1,500 revascularization procedures before randomizing any patients," Lal said. "These results provide hard data for the FDA and professional societies to use as they recommend a particular type or extent of training for performing these procedures." Monitoring of CREST participants will continue through 10 years.
Co-authors are: Kirk E. Beach, M.D., Ph.D.; Gary S. Roubin, M.D.; Helmi L. Lutsep, M.D.; Wesley S. Moore, M.D.; Mahmoud B. Malas, M.D.; David Chiu, M.D.; Nicole R. Gonzales, M.D.; James L. Burke, M.D.; Michael Rinaldi, M.D.; James R. Elmore, M.D.; Fred A. Weaver, M.D.; Craig R. Narins, M.D.; Malcolm Foster, M.D.; Kim Hodgson, M.D.; Alexander D. Shepard, M.D.; James F. Meschia, M.D.; Robert O. Bergelin, M.S.; Jenifer Voeks, Ph.D.; George Howard, Dr.P.H.; and Thomas G. Brott, M.D. Author disclosures are on the abstract.
The study is funded by the National Institute of Neurological Disorders and Stroke and Abbott Vascular Solutions (formerly Guidant), which included donations of the Acculink and Accunet stent systems to most of the CREST centers.
Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.